Despite its frequency, iron deficiency anemia in patients with IBD it is often overlooked in clinical settings.
The researchers found that OS was superior in IST responders. Shorter relapse-free survival (RFS) was seen with partial response to IST compared with complete response.
In vitro data have shown that eculizumab impairs meningococcal killing in whole blood despite patients being vaccinated against the appropriate serogroup. The current vaccines against meningococcal disease only target serogroup-specific proteins and do not provide protection against nongroupable N. meningitidis.
Vidaza is indicated as treatment for myelodysplastic syndrome (MDS), specifically refractory anemias and chronic myelomonocytic leukemia; it can be given either subcutaneously (SC) or intravenously (IV).
The researchers found that the mean hemoglobin increased from 7.9 to 11.9 g/dL in the ferrous sulfate group, compared with 7.7 to 11.1 g/dL in the iron polysaccharide complex group (greater difference of 1.0 g/dL with ferrous sulfate).
The FDA will consider the Committee's recommendation before acting on the biologics license application (BLA) for the epoetin alfa biosimilar.
An efficacy study of L-glutamine (Study 09-01) showed that the treatment resulted in a lower frequency of sickle cell painful crises, longer time to first and second crisis compared to placebo.
The patient underwent a non-myeloablative (NMA) peripheral blood stem cell transplant from a 10/10 HLA Ag matched, ABO incompatible unrelated donor.
The researchers documented warm autoimmune hemolytic anemia following babesiosis in patients with no history of autimmunity, they said there was no alternative explanation for clinical hemolysis.
The labeling for Lamisil (terbinafine hydrochloride) Tablets and Oral Granules has been updated to include a new warning regarding the risk of thrombotic microangiopathy.
High-dose crizanlizumab treatment is associated with a significantly lower rate of sickle cell-related pain crises than placebo, according to a new study
Emmaus Life Sciences has announced that the Food and Drug Administration (FDA) has accepted their New Drug Application (NDA) for its orally administered pharmaceutical grade L-glutamine (PGLG) treatment for sickle cell disease.
Emmaus Life Sciences announced its submission, with request for Priority Review, to the Food and Drug Administration (FDA) a New Drug Application (NDA) for an orally administered pharmaceutical grade L-glutamine (PGLG) for the treatment of sickle cell disease in adults and pediatric patients.
Anemia may increase mortality risk for older stroke patients, according to research published online in the Journal of the American Heart Association.
Sickle cell trait is not associated with a higher risk of death than absence of the trait, but it is associated with a significantly increased risk of exertional rhabdomyolysis, according to a study published in the August 4 issue of the New England Journal of Medicine.
Treatment with ferumoxytol for patients with iron deficiency anemia (IDA) and comorbid gastrointestinal disorders was found to be efficacious and generally well-tolerated in an analysis of a Phase 3 trial.
Children with sickle cell disease had improved lung function after treatment with hydroxyurea, according to a study presented at the American Thoracic Society (ATS) 2016 International Conference.
The use of intravenous (IV) or oral iron with or without an erythropoiesis-stimulating agent (ESA) may help prevent post-operative anemia and reduce blood transfusion without significantly raising the risk of adverse events, study authors reported in a study published in Annals of Pharmacotherapy.
Rockwell Medical announced that the Food and Drug Administration (FDA) has approved Triferic (ferric pyrophosphate citrate) powder packet for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (CKD).
New mutations have been identified with next-generation sequencing (NGS) in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T), which are prognostic for survival, according to a study published online in the American Journal of Hematology.
Amgen announced positive results from the Phase 3 ARCADE study evaluating Aranesp (darbepoetin alfa) in anemic patients with low and intermediate-1 risk myelodysplastic syndrome (MDS).